Plus Therapeutics, Inc. (NASDAQ: PSTV) reported Q1 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $506 thousand versus the consensus estimate of $600 thousand.

For earnings history and earnings-related data on Plus Therapeutics, Inc. (PSTV) click here.